Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
BJU International|March 1, 2012
A 970 Hounsfield units (HU) threshold of kidney stone density on non-contrast computed tomography (NCCT) improves patients' selection for extracorporeal shockwave lithotripsy (ESWL): evidence from a prospective studyIdir Ouzaid, Said Al-qahtani, Sébastien Dominique, et al.
Urology|October 18, 2002
Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trialBob Djavan, Mesut Remzi, Alexandre R Zlotta, et al.
BJU International|July 16, 2011
The use of estramustine phosphate in the modern management of advanced prostate cancerVincent Ravery, Karim Fizazi, Stephane Oudard, et al.
Urology|January 1, 2013
The learning curve of transrectal ultrasound-guided prostate biopsies: implications for training programsAmine Benchikh El Fegoun, Rabii El Atat, Laurence Choudat, et al.
Radiation Oncology (London, England)|October 26, 2018
Urinary function and quality of life after radiotherapy for prostate cancer in patients with prior history of surgical treatment for benign prostatic hyperplasiaMélanie Guilhen, Christophe Hennequin, Idir Ouzaid, et al.
European Urology|December 8, 2004
Are repeat biopsies required in men with PSA levels < or =4 ng/ml? A Multiinstitutional Prospective European StudyBob Djavan, Yan Kit Fong, Vincent Ravery, et al.
Clinical Nuclear Medicine|August 8, 2015
18F-Choline PET/CT and Prostate MRI for Staging Patients With Biochemical Relapse After Irradiation for Prostate CancerLaurent Quero, Laetitia Vercellino, Eric de Kerviler, et al.
Urologic Oncology|April 15, 2004
Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implicationsZivko Popov, Sixtina Gil-Diez-De-Medina, Vincent Ravery, et al.
Urology|September 15, 2015
The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter StudyCamille Couffignal, François Desgrandchamps, Pierre Mongiat-Artus, et al.
BMC Cancer|September 3, 2016
Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancerJean-Pierre Roperch, Bernard Grandchamp, François Desgrandchamps, et al.
Pageof 5